SEC Ends Chiron Probe
The US Securities and Exchange Commission (SEC) has ended its investigation of whether Chiron Corporation (Emeryville, CA, www.chiron.com) violated federal security laws in connection with the previous suspension of Chiron’s license to manufacture “Fluvirin” influenza virus vaccine by the UK Medicines and Healthcare Products Regulatory Agency.
The US Securities and Exchange Commission (SEC) has ended its investigation of whether Chiron Corporation (Emeryville, CA, www.chiron.com) violated federal security laws in connection with the previous suspension of Chiron’s license to manufacture “Fluvirin” influenza virus vaccine by the UK Medicines and Healthcare Products Regulatory Agency, according to a company statement. The SEC has also ended its inquiry into Chiron’s restatement of financial results for the second and third quarters of 2004.
Chiron says it has been informed that no enforcement action has been recommended against the company in connection with these matters.
Separately, the European Commission has approved Novartis AG’s (Basel, Switzerland, www.novartis.com) proposed acquisition of Chiron. This follows approval by US Federal Trade Commission and clearance by the Committee on Foreign Investment in the US under Exon-Florio.
Chiron and Novartis expect the transaction to be completed in the first half of 2006, subject to stockholder approval.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
